Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a special diet help IBS patients with flexible joints?

NCT ID NCT03460613

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at nearly 500 people with stomach and bowel problems to see if a low-FODMAP diet helps reduce symptoms. Researchers also checked for joint hypermobility (very flexible joints) and how the gut microbiome might be linked. The goal is to better understand who benefits most from dietary changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FODMAP diet
What this could lead to
If successful, this could help identify which IBS patients benefit most from a low-FODMAP diet, leading to more personalized dietary advice.
What could go wrong
This is an observational study with a dietary intervention, not a controlled trial. Results may not apply to all IBS patients, and dietary changes can be hard to maintain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

498 people

The number who actually took part.

Started

Jul 2017

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for FGID patients: * Functional bowel disease as per physician's diagnosis (medical judgement) and Rome IV criteria * Signed Informed Consent after being informed * Age 18-60 years Inclusion criteria for hepatology control cohort: * Signed Informed Consent after being informed * Age 18-60 years * Patient in the ambulatory hepatology clinic Inclusion criteria for healthy volunteers: * Signed informed consent after being informed * Age 18-60 years Exclusion criteria for FGID patients: * Inflammatory bowel disease * Gastrointestinal malignancy * Celiac Disease * Known or suspected non-compliance, drug or alcohol abuse * Previous large abdominal surgery likely to impact patient symptomatology * Inability to follow the procedures of the study, e.g. due to language problems, dementia, etc. of the participant * Previous enrollment into the current study * Use of antibiotics in the previous 4 weeks before enrolment Exclusion criteria for hepatology control cohort: * Previous diagnosed functional gastrointestinal disorders Exclusion criteria for healthy volunteers: * Previous diagnosed functional gastrointestinal disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional dyspepsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system disorder dyspepsia irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Functional gastrointestinal disorders

Contacts and locations

Locations

  • UniversitätsSpital

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.